Literature DB >> 26362386

Repackaged sodium valproate tablets--Meeting quality and adherence to ensure seizure control.

Nichola Redmayne1, Sherryl Robertson2, Jutta Kockler2, Victoria Llewelyn2, Alison Haywood3, Beverley Glass4.   

Abstract

PURPOSE: Sodium valproate, which is commonly repacked to assist with adherence to ensure seizure control, is hygroscopic and therefore sensitive to moisture. The aim of this study was thus to determine the stability implications of removing the enteric coated tablets from their original packaging and repackaging into a Dose Administration Aid (DAA) with storage under various environmental conditions.
METHODS: Physicochemical stability of enteric coated sodium valproate tablets repackaged into a DAA and stored at controlled room temperature, accelerated and refrigerated conditions was evaluated for 28 days. A validated high performance liquid chromatography method was used for the quantitation of the drug content.
RESULTS: Although the chemical stability (sodium valproate between 95 and 105% of labelled content) was maintained for 28 days for all storage conditions, for those tablets stored under accelerated conditions the integrity of the enteric coat was compromised after only 8 days.
CONCLUSIONS: Repackaging of enteric coated sodium valproate should be undertaken with caution and be informed by storage climate. This is particularly relevant for those patients living in hot, humid environments where they should be advised to store their DAA in a refrigerator.
Copyright © 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adherence; Dose Administration Aids; Enteric coating; Epilepsy; Packaging; Stability

Mesh:

Substances:

Year:  2015        PMID: 26362386     DOI: 10.1016/j.seizure.2015.07.007

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  5 in total

1.  Stability of repackaged dabigatran etexilate capsules in dose administration aids.

Authors:  Sherryl G Robertson; Beverley D Glass
Journal:  Eur J Hosp Pharm       Date:  2017-04-06

2.  Addressing varenicline adherence through repackaging in a dose administration aid.

Authors:  Aaron D Drovandi; Sherryl G Robertson; Bunmi S Malau-Aduli; Peta Ann Teague; Beverley D Glass
Journal:  Integr Pharm Res Pract       Date:  2017-06-23

3.  Telmisartan Tablets Repackaged into Dose Administration Aids: Physicochemical Stability under Tropical Conditions.

Authors:  Anthony P Ma; Sherryl G Robertson; Beverley D Glass
Journal:  Pharmaceutics       Date:  2022-08-11       Impact factor: 6.525

4.  Stability of medicines after repackaging into multicompartment compliance aids: eight criteria for detection of visual alteration.

Authors:  Valerie Albert; Michael Lanz; Georgios Imanidis; Kurt E Hersberger; Isabelle Arnet
Journal:  Drugs Ther Perspect       Date:  2017-07-26

Review 5.  Climate change and epilepsy: Insights from clinical and basic science studies.

Authors:  Medine I Gulcebi; Emanuele Bartolini; Omay Lee; Christos Panagiotis Lisgaras; Filiz Onat; Janet Mifsud; Pasquale Striano; Annamaria Vezzani; Michael S Hildebrand; Diego Jimenez-Jimenez; Larry Junck; David Lewis-Smith; Ingrid E Scheffer; Roland D Thijs; Sameer M Zuberi; Stephen Blenkinsop; Hayley J Fowler; Aideen Foley; Sanjay M Sisodiya
Journal:  Epilepsy Behav       Date:  2021-02-10       Impact factor: 3.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.